Evaluation of the Clinical Utility of the Bone Metastases Ensemble Trees for Survival Decision Support Platform (BMETS-DSP): A Case-Based Pilot Assessment Data on 221 newly diagnosed patients with AML ...
Dr. Daniel Peters discussed targeted therapies and regimens that patients with acute myeloid leukemia, or AML, should be aware of. During a recent visit to the Georgia Cancer Center, CURE sat down for ...
Herein, we report the results of an open-label, single-center phase II clinical trial evaluating the efficacy of azacitidine in the setting of MRD-triggered (decrease of CD34 + donor chimerism below ...
The VERONA trial showed no significant overall survival improvement with Venclexta plus azacitidine in intermediate/high-risk MDS patients compared to placebo. The combination arm demonstrated higher ...
Please provide your email address to receive an email when new articles are posted on . A 5-day azacitidine course had the most consistent survival benefit for low-risk MDS vs. other shorter ...
The goal of pharmaceutical intervention is to provide maximum therapeutic effectiveness with minimum risk to subjects. Orally administered medications allow for convenient dosing, but, because of ...
Azacitidine is standard, first-line therapy in higher-risk myelodysplastic syndromes (MDS). Whether azacitidine-based combinations with lenalidomide or vorinostat produce superior overall response ...
ORLANDO, Florida — For the first time, there is a maintenance therapy for patients with acute myeloid leukemia (AML) in remission that can improve overall survival — a new oral formulation of an old ...
LAKE ZURICH, Ill.--(BUSINESS WIRE)--Fresenius Kabi announced today the immediate availability in the United States of Azacitidine for Injection. Fresenius Kabi Azacitidine for Injection is available ...
The phase 3 VERONA trial did not meet the primary endpoint of overall survival. Topline data were announced from a phase 3 trial evaluating venetoclax (Venclexta ®) plus azacitidine for patients with ...
Please provide your email address to receive an email when new articles are posted on . The analysis included treatment-naive patients with AML who had been deemed unfit for intensive chemotherapy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback